Ypsomed, a medical device company with a focus on self-care solutions, has announced a continued focus on delivery systems such as their portfolio of self-injection devices. This follows previous announcements from Ypsomed regarding strategic changes to their business to better focus on their most successful areas.
At the J.P. Morgan healthcare conference, held from 12-15 January in San Francisco, Ypsomed announced that their business will now focus exclusively on their self-injection solutions for medications used to treat over 70 indications, including diabetes, obesity, and Alzheimer’s disease. Major strategic changes include the sales of their diabetes care segment and precision manufacturing businesses in 2025, and new manufacturing capabilities worldwide.
Go deeper with GlobalData
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
Ypsomed expects excellent market conditions for sales of their autoinjector devices for high volume markets, including delivery devices for autoimmune and incretin therapies. Incretins include rapidly growing treatments such as semaglutide and other GLP-1 receptor agonists. Ypsomed also expects favourable conditions for smaller volume markets, including delivery devices for cardiovascular therapies.
Ypsomed has seen high growth in their delivery device segment. From 2020 to 2025, the business grew at a compound annual growth rate of 24%, increasing from 211 million CHF in 2020 to 501 million CHF in 2025. Ypsomed expects this high growth rate to continue into 2026, with sales expected to reach 600 million CHF, representing an increase of 20%. The YpsoMate line of self-care autoinjectors has been especially successful due to the high growth of GLP-1 therapies.
To complement these high growth rates and increased demand, Ypsomed has also expedited their timeline for expansion to the US. A new manufacturing facility in North Carolina, planned for the final quarter of 2027, will give Ypsomed local production capability in the US market. This follows the announcement of another new manufacturing facility opening in Changzhou, China.
For the future, Ypsomed is well positioned to maintain its high growth in the delivery device market. With a new commitment to focus exclusively on delivery devices, it’s highly likely that Ypsomed will benefit from increased demand, especially autoinjectors used by patients at home.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSign up here to receive daily updates on the latest healthcare industry trends emerging from the JP Morgan Healthcare Conference 2026.
Sign up here to receive a comprehensive report after the conference.
